Skip to main content
. 2014 Nov 5;1329(1):93–106. doi: 10.1111/nyas.12567

Figure 4.

Figure 4

Relative efficacy and safety of novel oral anticoagulants in AF. HRs and 95% CIs are shown for the primary efficacy end point of stroke or systemic embolism (solid symbols) and for ISTH major bleeding (open symbols) in the phase III warfarin-controlled registrational trials for apixaban, rivaroxaban, and dabigatran.29,38,39